A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
about
Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.Small molecule purine and pseudopurine derivatives: synthesis, cytostatic evaluations and investigation of growth inhibitory effect in non-small cell lung cancer A549.Current Development Status of MEK Inhibitors.MEIS-1 level in unresectable hepatocellular carcinoma can predict the post-treatment outcomes of radiofrequency ablation.Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells.MEK inhibitors for the treatment of NRAS mutant melanomaUpdates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications
P2860
Q39366121-6217E144-2AA0-46C5-9A08-2B3D40EE0B1AQ47224821-784A7EEC-E15F-463C-B32A-0C7B7FC4F4B8Q47735535-E58F1C9E-33BB-415F-973B-F826734EE821Q54997807-047BE27A-8EC2-48F7-92E1-9247C3A3329EQ55086907-045E46CF-50DD-4DCA-BBF2-38622A17AAFFQ55438944-6DE30784-F813-4B96-8BE9-42F7C13D87B3Q56889985-C33B4F6C-7D1D-4916-81B6-98B4A2779137Q58760425-88B3BBC0-0D85-4335-B7E4-6CEA5E05DA15
P2860
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
A phase Ib study of selumetini ...... epatocellular carcinoma (HCC).
@en
type
label
A phase Ib study of selumetini ...... epatocellular carcinoma (HCC).
@en
prefLabel
A phase Ib study of selumetini ...... epatocellular carcinoma (HCC).
@en
P2093
P2860
P356
P1433
P1476
A phase Ib study of selumetini ...... epatocellular carcinoma (HCC).
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDW415
P577
2016-09-28T00:00:00Z